Consensus Alector, Inc.

Stocks

ALEC

US0144421072

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 16/09/2026 +04			5-day change	1st Jan Change
2.035 ^USD	-7.92%		-17.61%	+30.45%

09-15	Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM
09-15	Alector, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02:10 PM

Evolution of the Average Target: Alector, Inc.

Evolution of the Target Price: Alector, Inc.

Changes in Analyst Recommendations: Alector, Inc.

db82.g8yDS52wg0yEoatHww0Bs0H3pMOxfu7lObYCUd_ZLUY.tqXNKffp8x3Xl541rW9V9Q-B_JnUNLG1feRFZJazbn66vOY51enxPcjUzA~d2de3ce780b853a79942c8788a925a67

Analysts' recommendations: Alector, Inc.

04-15	Alector Shares Rise After Cantor Fitzgerald Upgrade	MT
04-15	Cantor Fitzgerald Upgrades Alector to Overweight From Neutral	MT
03-10	Alector Shares Rise After BTIG Upgrade	MT
03-10	BTIG Upgrades Alector to Buy From Neutral, Price Target is $6	MT
22/10/25	Top Midday Decliners	MT
22/10/25	William Blair Downgrades Alector to Market Perform From Outperform	MT
22/10/25	TD Cowen Downgrades Alector to Hold From Buy	MT
22/10/25	BTIG Downgrades Alector to Neutral From Buy	MT
22/10/25	Cantor Fitzgerald Downgrades Alector to Neutral From Overweight	MT
22/10/25	Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $1.50 From $3.50	MT
28/07/25	Alector Shares Rise After Mizuho Upgrade	MT
28/07/25	Mizuho Upgrades Alector to Outperform From Neutral, Raises Price Target to $3.50 From $2.50	MT
17/12/24	Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $2.50 From $9	MT
16/12/24	Stifel Downgrades Alector to Hold From Buy, Adjusts Price Target to $4 From $15	MT
04/12/24	BofA Securities Downgrades Alector to Underperform	MT
14/12/23	Stifel Upgrades Alector to Buy From Hold, Adjusts Price Target to $15 From $8	MT
12/12/23	Deutsche Bank Initiates Coverage on Alector With Buy Rating, $12 Price Target	MT
16/11/23	Mizuho Securities Trims Price Target on Alector to $9 From $10, Keeps Buy Rating	MT
22/09/23	Cantor Fitzgerald Starts Alector at Overweight With $13 Price Target	MT
11/08/23	Mizuho Cuts Price Target on Alector to $10 From $12, Keeps Buy Rating	MT
08/08/23	Stifel Adjusts Price Target on Alector to $8 From $10, Maintains Hold Rating	MT
05/05/23	Barclays Adjusts Price Target on Alector to $12 From $14, Maintains Overweight Rating	MT
03/03/23	Morgan Stanley Adjusts Price Target on Alector to $10 From $11, Maintains Equal-Weight Rating	MT
02/03/23	BTIG Adjusts Price Target on Alector to $16 From $54, Keeps Buy Rating	MT
02/03/23	Mizuho Adjusts Price Target on Alector to $12 From $15, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALECTOR, INC.					+52.33%
	WUXI APPTEC CO., LTD.					+19.4%
	ARGENX SE					+18.95%
	INSMED INCORPORATED					+66.4%
	WUXI BIOLOGICS (CAYMAN) INC.					+18.1%
	BIONTECH SE					+22.48%
	GENMAB A/S					+14.13%
	PHARMAESSENTIA CORPORATION					+15.96%
	SUMMIT THERAPEUTICS INC.					+67.21%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+34.01%
	Average					+32.90%
	Weighted average by Cap.					+26.64%